Skip to main content

Table 2 Univariate analysis of patient survival according to clinicopathologic characteristics

From: Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients

  5-year DFS rate (%) P 5-year OS rate (%) P
Gender   0.313   0.601
 Male (n = 79) 53.4   60.7  
 Female (n = 57) 51.7   66.7  
Age (years)   0.643   0.475
 <65 (n = 95) 50.1   59.7  
 ≥65 (n = 41) 56.8   67.2  
Smoking status   0.541   0.312
 Never (n = 103) 56.5   70.6  
 Former or current (n = 33) 46.5   54.5  
Tumor size   0.214   0.295
 >3 cm (n = 89) 46.7   59.7  
 ≤3 cm (n = 43) 54.2   66.2  
Adjuvant chemotherapy   0.213   0.713
 Yes (n = 37) 59.1   67.9  
 No (n = 99) 49.0   60.3  
Grade   0.675   0.233
 Well (n = 57) 59.6   73.3  
 Moderate or poor (n = 79) 50.1   55.4  
Pleural involvement   0.769   0.961
 Yes (n = 69) 49.0   60.4  
 No (n = 67) 55.2   67.5  
Lymphatic and/or vessel invasion   0.045   0.112
 Yes (n = 12) 39.1   51.7  
 No (n = 124) 54.3   68.1  
Histological subtypes (IASLC/ATS/ERS)     
Lepidicpredominant   0.042   0.307
 Yes (n = 21) 75.2   80.8  
 No (n = 115) 50.8   59.3  
Acinarpredominant   0.782   0.443
 Yes (n = 39) 55..5   67.8  
 No (n = 97) 49.0   58.9  
Papillary predominant   0.401   0.405
 Yes (n = 38) 57.6   72.1  
 No (n = 98) 47.1   57.2  
Micropapillary predominant   0.041   0.175
 Yes (n = 22) 28.4   43.5  
 No (n = 114) 61.1.   62.9  
Solid predominant   0.049   0.211
 Yes (n = 14) 36.7   45.9  
 No (n = 122) 57.7   65.1  
Variants of invasive adenocarcinoma 0.315   0.306
 Yes (n = 2) 100   100  
 No (n = 134) 51.3   60.5  
  1. DFS, disease-free survival rate; OS, overall survival rate.